Major Research Areas
Molecular Pharmacology & Chemistry

Memorial Sloan-Kettering Cancer Center's SPORE in Prostate Cancer supports innovative translational research projects in their formative state. The purpose of this program is to encourage and recognize novel research with the potential to advance the standard for prevention, diagnosis, and treatment of prostate cancer, by lending support to these projects before they have sufficient external funding. Additionally, the developmental research program establishes a means for interaction with other major cancer research centers and the ten other institutions with SPOREs in prostate cancer.

Ongoing Projects

  • Integrin Signaling in Prostate Carcinoma Invasion
    Filippo Giancotti, MD, PhD

  • Establishment of a Murine Prostate Cancer Model of Adoptive Immunotherapy Directed Against Prostate-Specific Membrane Antigen (PSMA)
    Michael Sadelain, MD, PhD

  • Magnetic Resonance and Radionuclide Investigation of Choline Metabolism in Prostate Cancer
    Jason Koutcher, MD, PhD

  • Modulation of Prostate Tumor Cell Response to Radiation
    Adriana Haimovitz-Friedman, PhD

  • Expression and Functional Analysis of the Hepatocyte Growth Factor/ Scatter Factor Receptor in Prostate Cancer Metastasis
    Beatrice Knudsen, MD, PhD (Fred Hutchinson Cancer Research Center)

  • Rational Epitope-enrichment of a PSMA-encoding DNA Vaccine for CD8+ T Cell Induction and Immune Monitoring
    Polly Gregor, PhD; Jose Guervara, MD, PhD

  • Significance of Prostate-Specific Antigen and Kallikrein 2 (hK2) in Prostate Cancer
    Hans Lilja, MD, PhD

  • Clinical Implications of Altered Androgen Receptor Forms in Prostate Cancer
    Wayne Tilley, PhD (Australia's National Health and Medical research Council)

  • Development of New Blood-based Markers in Prostate Cancer
    Paul Tempst, PhD

  • Antibody Functionalized Carbon Nanotubes Targeting Prostate Cancer
    Debjit Chattopadhyay, PhD; David A. Scheinberg, MD, PhD

  • Using Array-Comparative Genomic Hybridization to Identify the biologic Basis of Clinical Aggressive Prostate Cancer in African-Americans
    Iman Osman, MD (Kaplan Comprehensive Cancer Center, NYU)

  • The Development of Nutlin, The Inhibitor of MDM2, for Prostate Cancer Therapy, According to P53 Status
    Gary Schwartz, MD

  • Characterization of Genomic Variation in the Kallikrein Genes and their association with Prostate Cancer
    Hans Lilja, MD, PhD

  • Characterization of Genomic Alterations in the Androgen Receptor in Metastatic Prostate Cancer by Fluorescence In-Situ Hybridization (FISH) Analysis and Sequence Analysis of Circulating Tumor Cells

  • Proteomics in Prostate Cancer
    Paul Tempst, PhD
PrintEmail This Page